Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Goh Kodama"'
Autor:
Sakuya Ito, Yosuke Nakayama, Goh Kodama, Kanji Ota, Kensei Taguchi, Yusuke Kaida, Sho-ichi Yamagishi, Kei Fukami
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background Some types of antihypertensive drugs may have pleiotropic effects in patients with chronic kidney disease (CKD). However, whether triple combination therapy with angiotensin II receptor blockers (ARBs), calcium channel blockers (C
Externí odkaz:
https://doaj.org/article/3431b0f383f847698cb1d45549a1a913
Autor:
Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama, Michiaki Usui, Michio Chiba, Atsuo Moriyama, Atsuko Ohara, Hiroshi Miyazaki, Tatsuyuki Kakuma, Kei Fukami
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalc
Externí odkaz:
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
Publikováno v:
Journal of Hypertension. 41:e374-e375
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afbe95d5d4a362690e7f0a68b068433e
https://doi.org/10.1097/01.hjh.0000916636.41543.d1
https://doi.org/10.1097/01.hjh.0000916636.41543.d1
Autor:
Kei Fukami, Goh Kodama, Sho-ichi Yamagishi, Sakuya Ito, Yosuke Nakayama, Kensei Taguchi, Kanji Ota, Yusuke Kaida
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-7 (2021)
Background Some types of antihypertensive drugs may have pleiotropic effects in patients with chronic kidney disease (CKD). However, whether triple combination therapy with angiotensin II receptor blockers (ARBs), calcium channel blockers (CCBs), and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ec3ce397e05de98d82426c75e8a5bf2
https://doaj.org/article/3431b0f383f847698cb1d45549a1a913
https://doaj.org/article/3431b0f383f847698cb1d45549a1a913
Autor:
Aki Minami, Takuma Hazama, Tatsuyuki Kakuma, Akiko Nagata, Kei Fukami, Ryo Shibata, Miki Sugiyama, Yoshifumi Wada, Nao Nakamura, Yusuke Kaida, Ryotaro Ando, Michio Chiba, Sakuya Ito, Atsuko Ohara, Atsuo Moriyama, Michiaki Usui, Yosuke Nakayama, Tomofumi Moriyama, Goh Kodama, Takaomi Otome, Yuka Kurokawa, Hiroshi Miyazaki, Takatoshi Kambe
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0375ca161c9872b89b845383b2e102
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
Publikováno v:
Journal of Hypertension. 41:e443
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60737d10824d150b94e051c06bf5331d
https://doi.org/10.1097/01.hjh.0000917384.68636.0e
https://doi.org/10.1097/01.hjh.0000917384.68636.0e
Autor:
Sakuya Ito, Kensei Taguchi, Yusuke Kaida, Goh Kodama, Tomofumi Moriyama, Yunosuke Yokota, Masami Shinohara, Kyoko Tashiro, Kei Fukami
Publikováno v:
Journal of Hypertension. 41:e374
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::447c4171283a73499cb4ce6859812243
https://doi.org/10.1097/01.hjh.0000916632.72666.1e
https://doi.org/10.1097/01.hjh.0000916632.72666.1e
Autor:
Tomofumi Moriyama, Kensei Taguchi, Yusuke Kaida, Sakuya Ito, Goh Kodama, Yunosuke Yokota, Makoto Nasu, Kei Fukami
Publikováno v:
Journal of Hypertension. 41:e417
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::982c03eeda4dc06572e51f6f8227cecd
https://doi.org/10.1097/01.hjh.0000917104.10733.81
https://doi.org/10.1097/01.hjh.0000917104.10733.81
Autor:
Yukie Kinoshita, Junko Yano, Sakuya Ito, Yunosuke Yokota, Goh Kodama, Kei Fukami, Kyoko Tashiro, Yusuke Kaida, Yosuke Nakayama
Publikováno v:
The Kurume Medical Journal. 66:153-160
BACKGROUND Carnitine plays a pivotal role in energy synthesis through β-oxidation in mitochondria. Serum and tissue levels of free carnitine are significantly decreased in dialysis patients, whereas acylcarnitine levels are increased. However, the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bbe12218a36856168f8bdf5d0e1863f
https://doi.org/10.2739/kurumemedj.ms663001
https://doi.org/10.2739/kurumemedj.ms663001
Autor:
Nao Nakamura, Mikiko Soejima, Takuma Hazama, Utako Ueda, Yosuke Nakayama, Ryo Shibata, Tomofumi Moriyama, Yoshiro Koda, Yuka Kurokawa, Kanji Ota, Yoshimi Takamiya, Yunosuke Yokota, Yusuke Kaida, Kei Fukami, Sakuya Ito, Junko Yano, Goh Kodama
Publikováno v:
Clinical and Experimental Nephrology
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in the polycystic kidney disease (PKD) gene. Although tolvaptan has benefits for renal involvement, the different effects depending on the gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16ef1c5e5bca1cf314786e8edcd109d
https://pubmed.ncbi.nlm.nih.gov/33141305
https://pubmed.ncbi.nlm.nih.gov/33141305